An Israeli company has developed a portable device that uses transcranial magnetic stimulation (TMS) to alleviate chronic pain. The device delivers non-invasive magnetic pulses to specific brain regions associated with pain perception.
Clinical trials conducted in 2025 have demonstrated significant pain relief for fibromyalgia patients following eight weeks of treatment. Patients reported up to a 30% reduction in pain intensity compared to those in placebo groups. Repetitive transcranial magnetic stimulation (rTMS) reduced pain in fibromyalgia for up to 8 weeks; while analgesic effects waned, functional improvements remained during extended maintenance at week 16.
This portable TMS device offers a non-pharmacological option for managing pain, allowing patients to administer sessions at home under medical supervision. rTMS is generally considered a safe procedure, with minimal side effects. Primary motor cortex stimulation with rTMS has been explored in other chronic pain conditions, mainly neuropathic pain, where it is currently indicated for use.